OneMedNet Inks Seven-Figure Multiyear Data Deal With Sublicensing Upside
ONMD sits 19% above its 52-week low of $4.9.
Summary
OneMedNet signed a seven-figure, multiyear agreement to supply first-party real-world data to an AI-enabled precision medicine company. The partner will use the data to train models and create a licensable derivative dataset, with OneMedNet earning recurring sublicensing revenue on each downstream license. This is the company's tenth channel partner and includes an option to expand volume and value. The deal follows a year-to-date bookings announcement of $16.2 million on September 18, reinforcing a pattern of accelerating commercial traction. The agreement adds a new revenue stream with recurring sublicensing, which could improve the company's cash position given its low cash balance of $0.4 million as of the last 10-Q.
At the time of this announcement, ONMD was trading at $5.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.9M. The 52-week trading range was $4.90 to $42.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.